ビット カジノ 入金 不要ug Discovery
We will taken on the challenge of “drug discovery innovation” to create new value by combining drug discovery technologies and disease research.
And also, we will expand target modalities and disease fields and pursue in-licensing initiatives in a wide range of areas to broaden our development pipeline, and proactive partnering activities.
Ph3 ～ Application submitted
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅢ(Sep 2022) | KRP-R120 / Interstitial lung disease: ILD (pulmonary sarcoidosis) |
aTyr pharma | It is a fusion protein drug having the action to suppress, by binding to neuropilin-2 (NRP2) receptor, the excessive activation of immune cells, and is a potential first-in-class therapy to treat inflammatory diseases such as pulmonary sarcoidosis. |
POC Project (Ph1 ～ Ph2)
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅠ(Aug 2022) | KRP-114VP / Overactive bladder | Merck | Additional Indication for Beova in pediatric patients. |
| PhⅠ(Apr 2021) | KRP-A218 | In-house | It is antiviral drug that suppresses viral growth by targeting host molecules. |
Licensing development (License-in)
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅡ(Dec 2019) ASKA Pharmaceutical |
AKP-009 / Benign Prostatic Hyperplasia |
ASKA Pharmaceutical | Novel androgen receptor modulator mode of action with the potential to exhibit prostatic shrinkage and to improve urinary function as a novel therapeutic agent for Benign Prostatic Hyperplasia. * Additional Ph1 study at a higher dose has been completed (ASKA) * Further steps is under consideration in response to the results of the re-conducted Ph1 study (ASKA) |
| Ph 1 Bayer (Germany) |
KRP-S124 (BAY2925976) / OSA |
Bayer | BAY2925976 works as an ADRA2C antagonist, helping to centrally reduce upper airway collapse. It is expected to improve the temporary apneas and hypopneas commonly observed in patients with OSA. License agreement to obtained the exclusive worldwide rights to manufacture, develop, and commercialize BAY2925976 and its backup compound.(Dec 2024) |
Licensing development (License-out)
| Stage/Overseas | Compound / Code | Licensee | Origin | Features |
|---|---|---|---|---|
| PhⅢ | KRP-203 | Priothera | In-house | Sphingosine-1-Phosphate Receptor Agonist. |
DTx
| Origin | Code | Proposed Indication | Note |
|---|---|---|---|
| SUSMED | KRP-DT123 | Tinnitus | Collaboration research and sales agreement for development of Digital Therapeutics (DTx) in otolaryngology Field (Nov 2022) Specified clinical trial is in progress. |
Option Agreement
| Ph 1 Biodol (France) |
BDT272 / Chronic pain etc |
Biodol | BDT272 is anticipated to demonstrate effective analgesic properties through the inhibition of FLT3, a receptor tyrosine kinase implicated in the pathogenesis and maintenance of chronic pain condition such as neuropathic pain. Option agreement to obtain an option for the license of the right to develop and commercialize BDT272 in Japan and other territories in Asia (excluding China) (Jan 2025) |
|---|